Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

Patients will have tests and exams to see if they are eligible for the clinical trial. First-line chemotherapy regimen: Paclitaxel/Carboplatin(repeat every 3 weeks, total of 6 cycles): * Paclitaxel: 175 mg/m², intravenous infusion, on day 1. * Carboplatin: AUC 5, intravenous infusion, on day 1. * For patients aged ≥70 years or those with comorbidities, the paclitaxel dose can be adjusted to 135 mg/m². Surufatinib(repeat every 3 weeks, total of 5 cycles): * Surufatinib is not used during the first postoperative cycle. * Starting from the second postoperative cycle, surufatinib is administered at a dose of 250 mg once daily, taken continuously. Maintenance Therapy Regimen: HRD-positive Patients: * Surufatinib: 250 mg once daily, taken continuously. * Olaparib: 300 mg twice daily, with doses taken 12 hours apart. Olaparib can be used for a maximum of 2 years. HRD-negative or HRD Status Unknown Patients: * Surufatinib: 250 mg once daily, taken continuously. Treatment continues until the patient experiences disease progression or meets other criteria for discontinuation of the study treatment as specified in the protocol.